Fig. 7

Combination of CSF1-Fc + G-CSF treatment improved the reconstitution potential of mobilised HSPC. a Schematic of competitive transplantation assay. Briefly, female donor C57BL/6 non-transgenic mice were treated with either once daily saline for 4 days followed by bi-daily G-CSF treatment (saline + G-CSF) 14 days later or once daily CSF1-Fc for 4 days followed by bi-daily G-CSF treatment (CSF1-Fc + saline) 14 days later as in Fig. 5a. At 17 days post-initial CSF1-Fc treatment blood was harvested from donor C57BL/6 mice from the two different treatment groups and then independently pooled with competitor BM from transgenic RFP mice and transplanted into lethally irradiated B6.SJL Ptprca recipients. Tail bleeds were performed at 8, 12 and 16 week post-transplantation to determine chimerism. b Quantification of blood chimerism of RFP^negCD45.2⁺ donors (white bars) and RFP⁺CD45.2⁺ competitors (red bars) in recipient mice that were transplanted with blood from saline + G-CSF or CSF1-Fc + G-CSF-treated donor mice. c Number of repopulating units (RU) per ml of blood transplanted in grafts collected from saline + G-CSF (light blue dots) and CSF1-Fc + G-CSF (black squares)-treated donors determined at 16 weeks post-competitive transplant. d Percent frequency of major mature cell lineages in peripheral blood contributed by test donor samples (saline + G-CSF or CSF1-Fc + G-CSF) in competitive transplant assay. Data are mean ± SD. Evidence of data distribution non-normality was identified by the Kolmogorov–Smirnov test, and statistical analysis was performed on data using by a Mann–Whitney U test where **p < 0.01 and *p < 0.05